Literature DB >> 19096867

Preserved expression of fibroblast growth factor (FGF)-2 and FGF receptor 1 in brain and spinal cord of amyotrophic lateral sclerosis patients.

Susanne Petri1, Klaus Krampfl, Kerstin Kuhlemann, Reinhard Dengler, Claudia Grothe.   

Abstract

Impaired trophic support of motor neurons appears to be an important pathogenic factor in amyotrophic lateral sclerosis (ALS). We investigated the mRNA expression of the pluripotent fibroblast growth factor 2 (FGF-2) and its receptors in post mortem spinal cord of ALS and control patients. FGF-2 and FGF receptor (FGFR) 1 and 2 transcripts were first studied in the spinal cord using RT-PCR. The cellular distribution of FGF-2 and FGFR mRNA in the spinal cord, motor cortex and brain stem was then assessed by in situ hybridization histochemistry. RT-PCR revealed the presence of FGF-2 and FGF receptor 1 and 2 transcripts with no obvious differences between ALS and control spinal cord. Comparing mRNA expression in the motoneuron-containing ventral horn with the clinically and neuropathologically spared dorsal horn of ALS spinal cord displayed similar expression levels. At the cellular level, we found a prominent neuronal expression of FGF-2 and FGFR1. Interestingly, both morphologically intact and damaged motoneurons showed positive staining for FGF-2 and FGFR1 transcripts. The distribution of cells expressing FGF-2 and FGFR1 transcripts showed no differences between ALS and controls. Our data suggest that FGF-2 and FGFR1 expression is preserved in the motor system in end stage ALS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096867     DOI: 10.1007/s00418-008-0549-x

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  81 in total

1.  A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III).

Authors: 
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

2.  A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain.

Authors:  A M Gonzalez; M Berry; P A Maher; A Logan; A Baird
Journal:  Brain Res       Date:  1995-12-01       Impact factor: 3.252

Review 3.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics.

Authors:  Piera Pasinelli; Robert H Brown
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

4.  Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene.

Authors:  Yasuyuki Ohta; Makiko Nagai; Tetsuya Nagata; Tetsuro Murakami; Isao Nagano; Hisashi Narai; Tomoko Kurata; Mito Shiote; Mikio Shoji; Koji Abe
Journal:  J Neurosci Res       Date:  2006-10       Impact factor: 4.164

5.  Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons.

Authors:  D Pennica; V Arce; T A Swanson; R Vejsada; R A Pollock; M Armanini; K Dudley; H S Phillips; A Rosenthal; A C Kato; C E Henderson
Journal:  Neuron       Date:  1996-07       Impact factor: 17.173

6.  Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.

Authors:  Li-Jun Wang; Yan-Yan Lu; Shin-ichi Muramatsu; Kunihiko Ikeguchi; Ken-ichi Fujimoto; Takashi Okada; Hiroaki Mizukami; Takashi Matsushita; Yutaka Hanazono; Akihiro Kume; Toshiharu Nagatsu; Keiya Ozawa; Imaharu Nakano
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

7.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

8.  Immunohistochemical study on the distribution of insulin-like growth factor I (IGF-I) receptor in the central nervous system of SOD1(G93A) mutant transgenic mice.

Authors:  Yoon Hee Chung; Kyeung Min Joo; Chung Min Shin; Yun Jung Lee; Dong Hoon Shin; Kyung Hoon Lee; Choong Ik Cha
Journal:  Brain Res       Date:  2003-12-24       Impact factor: 3.252

9.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  Basic fibroblast growth factor in the chick embryo: immunolocalization to striated muscle cells and their precursors.

Authors:  J Joseph-Silverstein; S A Consigli; K M Lyser; C Ver Pault
Journal:  J Cell Biol       Date:  1989-06       Impact factor: 10.539

View more
  3 in total

Review 1.  Extending the knowledge in histochemistry and cell biology.

Authors:  Wolfgang-Moritz Heupel; Detlev Drenckhahn
Journal:  Histochem Cell Biol       Date:  2009-11-28       Impact factor: 4.304

2.  Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach.

Authors:  Giovanna Morello; Antonio Gianmaria Spampinato; Francesca Luisa Conforti; Velia D'Agata; Sebastiano Cavallaro
Journal:  J Mol Neurosci       Date:  2017-02-24       Impact factor: 3.444

Review 3.  What Can We Learn from FGF-2 Isoform-Specific Mouse Mutants? Differential Insights into FGF-2 Physiology In Vivo.

Authors:  Friederike Freiin von Hövel; Ekaterini Kefalakes; Claudia Grothe
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.